Treatment of Raynaud's phenomenon with intravenous prostaglandin E1α-cyclodextrin improves endothelial cell injury in systemic sclerosis

Journal of Rheumatology

Volumn 28, Issue 4, 2001, Pages 786-794

  Gardinali, M ^a   Pozzi, M R ^a   Bernareggi, M ^a   Montani, N ^a   Allevi, E ^a   Catena, L ^a   Cugno, M ^a   Bottasso, B ^a   Stabilini, R ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Intercellular adhesion molecule 1; Prostaglandins; Raynaud's phenomenon; Systemic sclerosis; Tissue type plasminogen activator

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; PROSTAVASIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; ENDOTHELIUM INJURY; FEMALE; FLUSHING; HEADACHE; HUMAN; PERISTALSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAYNAUD PHENOMENON; SIDE EFFECT; SYSTEMIC SCLEROSIS;

ADULT; AGED; ALPHA-CYCLODEXTRINS; ALPROSTADIL; BIOLOGICAL MARKERS; CYCLODEXTRINS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNE SYSTEM; INJECTIONS, INTRAVENOUS; MIDDLE AGED; RAYNAUD DISEASE; REFERENCE VALUES; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 0035082683     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Connective tissue disease: A critical review of minimal requisites for diagnosis
2. Morphologic changes in the digital arteries of progressive systemic sclerosis (scleroderma) and Raynaud phenomenon
3. A-adrenoreceptors and cold-induced vasoconstriction in human finger skin
4. Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma
5. Lipid-derived autacoids. Eicosanoids and platelet-activating factor
6. 2)
7. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome; a double-blind controlled trial
8. 1 infusions for vascular insufficiency in progressive systemic sclerosis
9. 1 in Raynaud's syndrome
10. 1 in severe peripheral vascular disease
11. 1 on human platelet function
12. Pharmacological effects of iloprost (ZK36 374), a stable prostacyclin analogue, in man
13. Infusion of iloprost, a prostacycline analogue, for treatment of Raynaud's phenomenon in systemic sclerosis
14. Successful treatment of Raynaud's syndrome with iloprost, a chemically stable prostacyclin analogue
15. A double blind randomized, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases
16. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis
17. Intravenous iloprost infusion in patients with Raynaud's phenomenon secondary to systemic sclerosis; a multicenter, placebo-controlled, double-blind study
18. Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis
19. 1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders
20. Pharmaceutical applications of cyclodextrins. I. Drug solubilization and stabilization
21. 1 in systemic sclerosis
22. 1α-cyclodextrin treatment of Raynaud's phenomenon in patients with systemic sclerosis
23. Increased levels of circulating intercellular adhesion molecule-1 in patients with localized scleroderma
24. Soluble intercellular adhesion molecule-1 and soluble interleukin-2 receptors in scleroderma skin
25. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon
26. Plasma levels of tissue-type plasminogen activator and von Willebrand factor in patients with Raynaud's phenomenon
27. Induction of intercellular adhesion molecule-1 on primary and continuous cell lines by pro-inflammatory cytokines: Regulation by pharmacologic agents and neutralizing antibodies
28. Soluble serum interleukin-2 receptors in patients with systemic sclerosis
29. Preliminary criteria for the classification of systemic sclerosis (scleroderma)
30. Skin thickness score in systemic sclerosis: An assessment of inter-observer variability in three independent studies
31. Patterns of finger capillary abnormalities in connective tissue disease by "wide field" microscopy
32. Seasonal variation of Raynaud's phenomenon secondary to systemic sclerosis
33. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon
34. Controlled trial of nifedipine in the treatment of Raynaud's phenomenon
35. Calcium entry blocking agents in digital vasospasm (Raynaud's phenomenon)
36. Calcium channel blockers and Raynaud's disease
37. International study of ketanserin in Raynaud's phenomenon
38. Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders
39. Efficacy of alprostadil and iloprost in digital necrosis due to secondary Raynaud's phenomenon
40. Retrospective comparison of iloprost with other treatments for secondary Raynaud's phenomenon
41. Vascular involvement in systemic sclerosis
42. Elevated expression of b1 and b2 integrins, intercellular adhesion molecule-1, and endothelial leukocyte adhesion molecule-1 in the skin of patients with systemic sclerosis of recent onset
43. Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis
44. Circulating intercellular adhesion molecule-1 in patients with systemic sclerosis
45. Serum levels of soluble interleukin-2 receptor: A possible index of disease prognosis in systemic sclerosis
46. Elevated serum tumor necrosis factor-α levels in patients with systemic sclerosis: Association with pulmonary fibrosis
47. Soluble interleukin-2 receptors in patients with systemic sclerosis
48. Cytokine production and serum levels in systemic sclerosis
49. Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule-1 expression on scleroderma fibroblasts and endothelial cells by interferon γ and tumor necrosis factor α in the early disease stage
50. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis
51. Cytokine production in scleroderma patients: Effects of therapy with either iloprost or nifedipine
52. Regulation of tumor necrosis factor-a and interleukin-1b-induced adhesion molecule expression in human vascular smooth muscle cells by cAMP
53. Activation of cAMP-dependent pathways in human airway smooth muscle cells inhibits TNF-α-induced ICAM-1 and VCAM-1 expression and T lymphocyte adhesion
54. Elevated cyclic AMP inhibits endothelial cell synthesis and expression of TNF-induced endothelial leukocyte adhesion molecule-1, and vascular cell adhesion molecule-1, but not intercellular adhesion molecule-1
55. 1 inhibits TNF-α-induced T-cell adhesion to endothelial cells by selective down-modulation of ICAM-1 expression in endothelial cells
56. Effect of nonsteroidal anti-inflammatory drugs on LFA-1 and ICAM-1 expression in gastric mucosa
57. Protective effects of preconditioning in cultured rat endothelial cells: Effects on neutrophil adhesion and expression of ICAM-1 after anoxia and reoxygenation
58. Increase in oxygen tension stimulates expression of ICAM-1 and VCAM-1 on human endothelial cells
59. 1 protects against ischemia-reperfusion injury of the liver by inhibition of neutrophil adherence to endothelial cells
60. Iloprost added to the cardioplegic solutions improves myocardial performance
61. Clinical implications of soluble intercellular adhesion molecule-1 levels in systemic sclerosis
62. Continuous infusion of prostacyclin decreases plasma levels of t-PA and PAI-1 in primary pulmonary hypertension
63. Supranormal von Willebrand factor multimers in scleroderma
64. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension